Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer (COL)
Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49933
- Centre Paul Papin
-
Brest, France, 29200
- Centre Hospitalier Universitaire
-
Caen, France, 14046
- Centre François Baclesse
-
Lille, France, 59020
- Centre Oscar Lambret
-
Rennes, France, 35042
- Centre Eugene Marquis
-
Rouen, France, 76031
- CHU - Hopital Charles Nicolle
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven
- Treated by exclusive concomitant radiochemotherapy
- Written informed consent
Exclusion Criteria:
- Presence of a second uncontrolled cancer
- Metastatic carcinoma
- Metastatic disease, except cervical lymphnodes... (M1a)
- In situ carcinoma
- Eso-gastric junction cancer (Siewert II ou III)
- Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry
Time Frame: 15 weeks after the end of irradiation
|
15 weeks after the end of irradiation
|
|
Initial complete clinical response
Time Frame: 15 weeks after the end of irradiation
|
15 weeks after the end of irradiation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prolonged clinical response at one year
Time Frame: One year after the end of irradiation
|
One year after the end of irradiation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: ADENIS Antoine, MD, PhD, Centre Oscar Lambret
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Investigative Techniques
- Therapeutics
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Physical Phenomena
- Inorganic Chemicals
- Chlorine Compounds
- Nitrogen Compounds
- Pyrimidines
- Uracil
- Pyrimidinones
- Platinum Compounds
- Fluorouracil
- Cisplatin
- Radiation
- Drug Therapy
- Blood Specimen Collection
Other Study ID Numbers
Other Study ID Numbers
- COL-0613
- 2006-A00568-43 (Other Identifier: AFSSAPS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.